In contrast, our study observed prolonged overall survival in NEC patients treated with pembrolizumab (S2A Fig), suggesting that PD-L1 expression may not be a reliable predictor of response in NEC. This evidence concerns the gene CD274 and neuroendocrine carcinoma.